The Swiss pharmaceuticals group Roche has announced its plans to buy the American BioVeris, a specialist in immunochemistry quoted on the NASDAQ index, for $600 million. The price has been set at $21.4 per share. The transaction will open up a new market, estimated at €250 million, to Roche.